MiraDx Reaps $1M Investment From Connecticut Innovations | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MircoRNA test developer MiraDx has received a $1 million investment through the Eli Whitney Fund of Connecticut Innovations, a technology-focused economic development group, CI said today.

For the firm, which is based in New Haven, Conn., the $1 million investment is part of its Series A round of financing that will add up to a total of $4 million, CI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.